SUJIT SANSGIRY to United States Food and Drug Administration
This is a "connection" page, showing publications SUJIT SANSGIRY has written about United States Food and Drug Administration.
Connection Strength
0.725
-
Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval. Clin Transl Oncol. 2024 Aug; 26(8):1908-1920.
Score: 0.217
-
Effectiveness of FDA's new over-the-counter acetaminophen warning label in improving consumer risk perception of liver damage. J Clin Pharm Ther. 2012 Dec; 37(6):681-5.
Score: 0.097
-
Risks, benefits, and issues in creating a behind-the-counter category of medications. J Am Pharm Assoc (2003). 2011 Jan-Feb; 51(1):26-39.
Score: 0.087
-
Evaluation of facsimile cards for pharmacy-access products containing pseudoephedrine or ephedrine. J Am Pharm Assoc (2003). 2008 Jan-Feb; 48(1):52-7.
Score: 0.070
-
Pseudoephedrine laws in the US--are we doing enough? Ann Pharmacother. 2006 Jun; 40(6):1213-5.
Score: 0.063
-
Use of the Internet for medication purchases and health information: can we make it safer? Mayo Clin Proc. 2005 May; 80(5):704; author reply 704-5.
Score: 0.059
-
Inconsistency in DTCA practices by manufacturers: is it time to standardize print summaries? Value Health. 2004 Mar-Apr; 7(2):216-7.
Score: 0.054
-
Consumer involvement: effects on information processing from over-the-counter medication labels. Health Mark Q. 2001; 19(1):61-78.
Score: 0.043
-
Readability of over-the-counter medication labels. J Am Pharm Assoc (Wash). 1997 Sep-Oct; NS37(5):522-8.
Score: 0.034